FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094664614> ?p ?o ?g. }

• W2094664614 endingPage "545" @default.
• W2094664614 startingPage "525" @default.
• W2094664614 abstract "Although their ultimate value in prostate cancer therapy remains to be defined in randomized trials, docetaxel and paclitaxel are active agents in HRPC. Combination therapies using either of these taxanes plus oral EMP show reproducible antitumor activity that appears to be greater and more durable than that of single-agent treatment. Although the optimal combination and schedule have not been determined, weekly paclitaxel and EMP and docetaxel given every 3 weeks or by weekly infusion with EMP are useful treatment options for patients with progressive HRPC. The gastrointestinal toxicity of EMP has been reduced by intermittent rather than continuous administration, and other toxicities may be reduced further by use of intravenous EMP. Although there has been progress, the median time to progression of 5 to 6 months for current taxane-based therapies suggests that they will not have major impact on overall survival for patients with HRPC. Greater benefit may be possible earlier in the course of prostate cancer, and the activity of the taxane-EMP combinations is sufficient to justify clinical trials of adjuvant or neoadjuvant chemotherapy for selected groups of patients with locally advanced and poor-prognosis tumors. Armed with many new molecularly targeted agents that may interact favorably with taxanes, it should be possible to build on current antimicrotubule regimens to improve activity in HRPC. Taxane-EMP combinations provide a platform on which to test additional agents that may enhance the apoptotic response or circumvent cellular stress adaptations that confer drug resistance. Further elucidation of signaling pathways that regulate microtubule dynamics and programmed cell death after exposure to microtubule inhibitors would provide a more rational guide for integrating specific inhibitors of signal transduction with current taxane-based therapies. Pharmacokinetic and pharmacodynamic studies will play a key role in the development of future taxane-based therapies for prostate cancer." @default.
• W2094664614 created "2016-06-24" @default.
• W2094664614 creator A5010671566 @default.
• W2094664614 creator A5016064449 @default.
• W2094664614 date "2001-06-01" @default.
• W2094664614 modified "2023-10-16" @default.
• W2094664614 title "PACLITAXEL AND DOCETAXEL IN PROSTATE CANCER" @default.
• W2094664614 cites W1515806093 @default.
• W2094664614 cites W1749876465 @default.
• W2094664614 cites W1816774827 @default.
• W2094664614 cites W1853704205 @default.
• W2094664614 cites W1868905893 @default.
• W2094664614 cites W1885306047 @default.
• W2094664614 cites W1893347245 @default.
• W2094664614 cites W1900605243 @default.
• W2094664614 cites W1905912155 @default.
• W2094664614 cites W1963614111 @default.
• W2094664614 cites W1964112264 @default.
• W2094664614 cites W1971541628 @default.
• W2094664614 cites W1977046340 @default.
• W2094664614 cites W1981534406 @default.
• W2094664614 cites W1991753768 @default.
• W2094664614 cites W1992546538 @default.
• W2094664614 cites W1996491270 @default.
• W2094664614 cites W1997241897 @default.
• W2094664614 cites W2004720674 @default.
• W2094664614 cites W2008407088 @default.
• W2094664614 cites W2012525123 @default.
• W2094664614 cites W2014184691 @default.
• W2094664614 cites W2018771702 @default.
• W2094664614 cites W2024463580 @default.
• W2094664614 cites W2028282570 @default.
• W2094664614 cites W2029967111 @default.
• W2094664614 cites W2031540448 @default.
• W2094664614 cites W2043172025 @default.
• W2094664614 cites W2043478531 @default.
• W2094664614 cites W2049455781 @default.
• W2094664614 cites W2050285145 @default.
• W2094664614 cites W2058917998 @default.
• W2094664614 cites W2060296835 @default.
• W2094664614 cites W2072833665 @default.
• W2094664614 cites W2080391833 @default.
• W2094664614 cites W2082238401 @default.
• W2094664614 cites W2094569820 @default.
• W2094664614 cites W2108929767 @default.
• W2094664614 cites W2109990295 @default.
• W2094664614 cites W2125089526 @default.
• W2094664614 cites W2141918532 @default.
• W2094664614 cites W2144626855 @default.
• W2094664614 cites W2145978772 @default.
• W2094664614 cites W2153284157 @default.
• W2094664614 cites W2162960688 @default.
• W2094664614 cites W2177330869 @default.
• W2094664614 cites W2184174775 @default.
• W2094664614 cites W2403518551 @default.
• W2094664614 cites W2415683488 @default.
• W2094664614 cites W4233628679 @default.
• W2094664614 doi "https://doi.org/10.1016/s0889-8588(05)70230-6" @default.
• W2094664614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11525295" @default.
• W2094664614 hasPublicationYear "2001" @default.
• W2094664614 type Work @default.
• W2094664614 sameAs 2094664614 @default.
• W2094664614 citedByCount "56" @default.
• W2094664614 countsByYear W20946646142013 @default.
• W2094664614 countsByYear W20946646142014 @default.
• W2094664614 countsByYear W20946646142015 @default.
• W2094664614 countsByYear W20946646142016 @default.
• W2094664614 countsByYear W20946646142017 @default.
• W2094664614 countsByYear W20946646142018 @default.
• W2094664614 countsByYear W20946646142019 @default.
• W2094664614 countsByYear W20946646142020 @default.
• W2094664614 countsByYear W20946646142021 @default.
• W2094664614 countsByYear W20946646142022 @default.
• W2094664614 countsByYear W20946646142023 @default.
• W2094664614 crossrefType "journal-article" @default.
• W2094664614 hasAuthorship W2094664614A5010671566 @default.
• W2094664614 hasAuthorship W2094664614A5016064449 @default.
• W2094664614 hasConcept C121608353 @default.
• W2094664614 hasConcept C126322002 @default.
• W2094664614 hasConcept C143998085 @default.
• W2094664614 hasConcept C2776235491 @default.
• W2094664614 hasConcept C2776694085 @default.
• W2094664614 hasConcept C2777292972 @default.
• W2094664614 hasConcept C2777511904 @default.
• W2094664614 hasConcept C2777863537 @default.
• W2094664614 hasConcept C2777899217 @default.
• W2094664614 hasConcept C2778971682 @default.
• W2094664614 hasConcept C2780192828 @default.
• W2094664614 hasConcept C2781190966 @default.
• W2094664614 hasConcept C530470458 @default.
• W2094664614 hasConcept C535046627 @default.
• W2094664614 hasConcept C71924100 @default.
• W2094664614 hasConcept C98274493 @default.
• W2094664614 hasConceptScore W2094664614C121608353 @default.
• W2094664614 hasConceptScore W2094664614C126322002 @default.
• W2094664614 hasConceptScore W2094664614C143998085 @default.
• W2094664614 hasConceptScore W2094664614C2776235491 @default.
• W2094664614 hasConceptScore W2094664614C2776694085 @default.

• next